


Remarks

The specification has been amended to correct an error in the chemical name of the compound prepared in Example 2. Thus, "[propyl]" has been added to the chemical name. The correction is supported by the synthetic procedure recited in Example 2 on page 20 and by the structure recited for Example 2 in Table I on page 18 of the specification. No new matter has been introduced by the instant amendment.

In Response to the Restriction Requirement mailed November 2, 2009, Applicant hereby elects Group I, claims 1-7 and 11 (in part), drawn to compounds of the formulae I and II in which Y is NR₃. Applicants elect the species of Example 2 for initial examination. Claims Applicants request rejoinder of Groups IV and VII upon allowance of the compound claims. Applicant elects without traverse.

Respectfully submitted,



John Alexander
Attorney for Applicants
Reg. No. 48,399

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Avenue
Cambridge, MA 02139
(617) 871-3105

Date: 2 December 2009